Summary The efficacy of currently available treatments for Hodgkin's disease (HD) has led to a substantial modification in the prognosis of this disease; nevertheless there is still a group of patients that cannot be cured with conventional treatments and who will be candidates for alternative therapy. In the present work we analysed the prognostic influence of the most relevant clinico-biological characteristics of HD in a consecutive series of 137 patients diagnosed and treated in a single institution. Univariate analyses identified six variables with significant prognostic influence, both on achieving complete remission (CR) and overall survival (OS); LDH >320 U ml-', age >45 years, stages IIB, III and IV, extranodal involvement, alkaline phosphatase >19OUIdl and ESR >40mmh. In addition, Hb<12.5grdl-' and abdominal disease were statistically relevant for CR while a poor performance score (ECOG ) 2) affected a lower survival. In the multivariate analysis only LDH, age and the clinical stage retained a significant prognostic influence for achieving CR, while the two first factors above, together with performance status were the variables with independent prognostic value with respect to OS. Moreover, only LDH >320Uml-' had prognostic influence in the probability of relapse and disease free survival (DFS), both in the univariate and multivariate analyses.
The prognostic outlook for Hodgkin's disease (HD) has markedly improved in recent decades and today 70 to 80 percent of these patients can be cured with chemotherapy and/or radiotherapy (Bonadonna et al., 1988; Canellos, 1992 ; Urba & Long, 1992) . This progressive improvement has been based on adequate prospective therapeutic trials combined with careful clinicopathologic and prognostic factor analysis (Bennett et al., 1983; Desch et al., 1992; Hoppe et al., 1982; Loefler et al., 1988; Specht et al., 1988; Strauss et al., 1990; Tubiana et al., 1989; Wedelin et al., 1984) . However, there is still a group of patients refractory to initial treatment that will be candidates for alternative therapeutic approaches (Gribben et al., 1989; Jagannath et al., 1986; Yahalom et al., 1989) . The definition of new prognostic factors that allows the identification of such patients at the actual time of diagnosis will be of great value.
The serum levels of lactic acid dehydrogenase (LDH), which are very important in the prognosis of non-Hodgkin's lymphoma (NHL) (Danieu et al., 19881 Schneider et al., 1980) , have not received much attention in HD although recently Strauss et al. (1990) have stressed its value as an independent factor with even greater significance than other classical parameters, such as age. In addition, this parameter fulfills the requisites of a good prognostic factor in the sense that LDH levels are objective and readily accessible.
In the present work we analysed the prognostic influence of the different clinico-biological characteristics of HD in a consecutive series of 137 patients diagnosed and treated in a single institution, showing that the serum level of LDH is one of the variables with the greatest impact in the outcome of the disease. (Carbone et al., 1971) and the Cotswolds review (Lister et al., 1989 (Lukes et al., 1966 (Cox, 1972) was performed to examine the simultaneous effect of the different variables on the probability of achieving CR and the rate of relapse.
Materials and methods

Patients
The same characteristics mentioned above were newly considered for analysis with respect to their individual and simultaneous effects on overall survival (OS) and disease freed survival (DFS) -univariate and multivariate analysis, BMDP IL and 2L, respectively. OS and DFS curves were plotted according to the method of Kaplan and Meier, and compared statistically using the Mantel-Cox, Peto-Prentice and Breslow tests. The cut-off point of each variable was selected by starting at its median value and then cutting at different levels above and below, until significance was eventually obtained. Variables considered for possible inclusion in the regression analysis were those for which there was some indication of a significant association in univariate analysis (P<0.1) or for which prior studies had suggested a possible association. The stepwise regression procedure was stopped when the P value for entering an additional factor was above 0.05. The model was tested both by expressing values in a continuous way (continuous variables) and by grouping them into categories (dichotomous variables).
Results
The median age of this series of patients was 38 years (range 4-78) with a slight predominance of males (55%). In most patients (81%) HD was in the advanced stages. The histologic pattern included: 50% with nodular sclerosis, 32% with mixed cellularlity, 9% with lymphocyte predominance and 9% with lymphocyte depletion.
The overall rate of CR was 79%, with an incidence of relapse of 30%. At 7 years, OS was 81% and disease-free survival at 6 years, 61% (patients with a minimum follow-up of 36 months). there were no statistically significant differences among the different chemotherapeutic regimens employed.
Prognosticfactors for achieving complete remission (CR)
The results of the analysis of prognostic factors with respect to the probability of achieving CR are shown in Table I . In the univariate analysis, eight variables were significantly associated with a low probability of achieving CR: elevated LDH levels (P <0.0001), advanced age (P = 0.008), advanced stage (P = 0.001), abdominal disease (P = 0.003), extranodal involvement (P = 0.01), elevated alkaline phosphatase (AP) (P = 0.01), ESR higher than 40 mm h-' (P = 0.01), low level of hemoglobin (P = 0.02) and the presence of B symptoms (P = 0.03). In the multivariate analysis, only three factors retained a significant prognostic value: elevated LDH (P = 0.0001); age above 45 (P = 0.002), and the existence of an advanced stage of the disease (P = 0.03). According to the three independent factors obtained in the multivariate analysis (LDH, age and stage), a predictive model was established for stratifying the patients into two prognostic groups: one with poor prognosis that included patients with the three adverse prognostic factors, or two if one of them was elevated LDH (above the maximum limit of 320 U ml-'); the rest of the patients would be included in another group, which would afford them a good prognosis. The rates of CR were 16% and 90%, respectively.
Prognostic factors for overall survival (OS) The variables associated with a significantly lower survival in the univariate analysis were: age >45 years (P = 0.004), performance status -ECOG >i 2-(P = 0.002), LDH > 320 U mli' (P = 0.0005), ESR > 40 mm h-' (P = 0.04), extranodal involvement (P = 0.04), AP level> 190 UI dl (0.05) and advanced stage (P = 0.05) ( Table III) . The multivariate study showed that only three of them had independent prognostic value: advanced age (P = 0.003), elevated LDH levels (P = 0.02) and ECOG equal to or greater than 2 (P = 0.01). On eliminating the patients that died before the end of treatment (early deaths), the multivariate analyses showed that performance status (P = 0.13), advanced age (P = 0.29) and an ESR above 40 mm h-' (P = 0.18) lost their independent prognostic with respect to OS and the disease characteristics with significant influence were reduced to two: age above 45 years (P = 0.0005) and an LDH level above 320 U ml-' (P = 0.007). Figure 1 shows the survival curves for age and LDH levels.
Prognostic factors for relapse and disease free survival (DFS) Within the group of patients that achieved CR, there was only one variable that maintained prognostic significance for the prediction of relapse; this was the serum level of LDH, both in univariate (P = 0.009) and in multivariate (P = 0.002) analyses, the best cut-off being the maximum normal value, which was 320 U ml-'. Neither age nor the clinical stage of the disease were of help in the prediction of relapses. Regarding DFS, the LDH level was also the only parameter that at the time of diagnosis had statistically significant influence on DFS (P = 0.01). Figure 2 shows the DFS curves with respect to the serum LDH levels.
Interestingly, the stratification model of two prognostic groups established for CR was also able to separate them with respect to overall survival and disease-free survival (Figure 3 ).
Discussion
The efficacy of currently available treatments against HD have led to a substantial modification in the prognosis of this disease; nevertheless there is still one group of patients that cannot be cured with conventional treatments. In the present work we developed a prognostic model as regards the probability of achieving CR and predicting survival (OS and DFS).
In our series, ten clinical variables had prognostic influence (with respect to achieving CR or relapsing and with respect Months from start therapy Figure 1 Overall survival curves stratified according to (a) Age at diagnosis ( <45 years and >45 years); (b) LDH level at diagnosis ( < 320 U ml-' and > 320 U ml-'). (Anderson et al., 1985; Specht et al., p = 0.006 1985; Strauss et al., 1990 (, 320 U ml-' cally considered as an unfavourable prognostic factor in HD >320 U ml-') from complete remission. (Anderson et al., 1985; Carde et al., 1983; Desch et al., 1992; Jaffe et al., 1986; Specht et al., 1985 Specht et al., , 1988 Strauss et al., 1990; Tubiana et al., 1989 (Anderson et al., 1985; al., (Carde et al., 1983; Longo et al., 1986; Pillai et al., 1985) . )esch Jaffe et al., 1986; Specht et al., 1985, Additionally, some studies have reported that advanced age Strauss, et al., 1990; Tubiana et al., 1989) , advanced is associated with adverse histological subtypes and advanced stage (Kaplan, 1981; Urba & Long, 1992; Strauss et disease (Strauss et al., 1990) , as was the case of the series )0; Wedelin et al., 1984) , elevated AP levels (Loefler et described here (Table II) . The effect of an advanced stage of 38), abdominal disease (Leibenhaut et al., 1987;  Strauss the disease on the probability of achieving CR has also been 1990; Villamor et al., 1991) , raised ESR (Loefler et al., reported in other reports (Kaplan, 1981; Strauss et al., 1990; Tubiana et al., 1984 Tubiana et al., , 1989 , B symptoms and low Urba & Long, 1992) ; indeed, all our patients in stages IA lobin levels (CrnKovich et al., 1987; Jaffe et al., 1986; and IIA achieved CR. et al., 1986; Strauss et al., 1990) . Other prognostic LDH, broadly studied as a predictive variable in nondetected in different studies, such as the existence of Hodgkin lymphomas, has received less attention in HD. The more extranodal sites involved (Strauss et al., 1990) first time that it was related to the outcome of HD was in lymphocyte counts (Specht et our series, it proved to be the parameter with the greatest independent strength with respect to achieving CR. As regards survival, LDH was selected after age and performance status. Nevertheless, on discounting early deaths, the statistical influence of LDH increased while performance status lost its prognostic value. Additionally, LDH was the only variable that had independent predictive value as regards relapse and DFS. This, together with the simplicity in determining its levels and its objective nature, increases its usefulness in clinical practice. Interestingly our study shows that LDH levels were associated with most of the disease characteristics that reflect high tumour burden. Finally, in the present study we propose a prognostic model in which LDH is of great value for the identification of a particular group of patients with a high probability of treatment failure and who are therefore candidates for new therapeutic strategies at the actual time of diagnosis, such as high doses in chemotherapy followed either by autologous bone marrow transplantation or growth-factor administration.
